At the time of writing, ORIC Pharmaceuticals Inc [ORIC] stock is trading at $13.68, down -2.84%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ORIC shares have gain 18.29% over the last week, with a monthly amount glided 25.97%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Ladenburg Thalmann started tracking the stock with Buy rating on July 08, 2025, and set its price target to $15. On October 31, 2024, Wells Fargo initiated with a Overweight rating and assigned a price target of $20 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $20 on September 06, 2024. Cantor Fitzgerald initiated its recommendation with a Overweight. Wedbush started tracking with a Outperform rating for this stock on September 22, 2023, and assigned it a price target of $8. In a note dated March 23, 2023, H.C. Wainwright upgraded a Buy rating on this stock but restated the target price of $16.
For the past year, the stock price of ORIC Pharmaceuticals Inc fluctuated between $3.90 and $14.93. Currently, Wall Street analysts expect the stock to reach $15 within the next 12 months. ORIC Pharmaceuticals Inc [NASDAQ: ORIC] shares were valued at $13.68 at the most recent close of the market. An investor can expect a potential return of 9.65% based on the average ORIC price forecast.
Analyzing the ORIC fundamentals
Gross Profit Margin for this corporation currently stands at -0.33% with Operating Profit Margin at -140.4%, Pretax Profit Margin comes in at -128.75%, and Net Profit Margin reading is -128.75%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.52 and Total Capital is -0.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that ORIC Pharmaceuticals Inc [NASDAQ:ORIC] has a current ratio of 16.13. In addition, the Quick Ratio stands at 16.13 and the Cash Ratio stands at 4.2.
Transactions by insiders
Recent insider trading involved Piscitelli Dominic, Chief Financial Officer, that happened on Oct 06 ’25 when 11000.0 shares were sold. PRESIDENT AND CEO, Chacko Jacob completed a deal on Oct 06 ’25 to sell 37461.0 shares. Meanwhile, Officer Dominic Piscitelli bought 50000.0 shares on Oct 06 ’25.
